AtriCure Reports Second Quarter 2026 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/1/2026
- Wall St futures gain as AI, consulting stocks offset bond-market jitters
- Oil prices rise 2% as China suspends fuel exports
- Amazon and these four U.S. stocks are latest additions to Goldman’s flagship list
- Elevated equity positioning, leverage could challenge stocks in Q4: JPMorgan
- Alphabet shares up in premarket trade after Gemini 4 Argon launch
- Zimbabwe helicopter crash kills six, government spokesperson says
- Apple's iOS 27 is blocking Trade Desk ads on Safari, analyst says
- S&P 500 dips, Nasdaq higher after data shows moderate inflation rise
- DataMeds AI's Corexa Pharmacy tops $1M in monthly revenue
- Mattel names Roger Lynch as chairman and CEO, replacing Ynon Kreiz
AtriCure (ATRC) Tops Q2 EPS by 19c, Beats on Revenue; Offers FY26 EPS Guidance
July 23, 2026 4:15 PM EDTAtriCure (NASDAQ: ATRC) reported Q2 EPS of $0.18, $0.19 better than the analyst estimate of ($0.01). Revenue for the quarter came in at $153.6 million versus the consensus estimate of $151.84 million.
GUIDANCE:
AtriCure sees FY2026 EPS of $0.24-$0.32, versus the consensus of $0.12.
For earnings history and earnings-related data on AtriCure (ATRC) click here.
... More